Merck halts small cell lung cancer immunotherapy drug trial
Merck has stopped an end-stage combination immunotherapy trial for a lung cancer condition, following recommendations of an independent data monitoring committee, which indicated.
Drugs
Health
Pharma
Drugs
Health
Pharma
Daiichi Sankyo to pay Merck $170 million for cancer test drug rights
Daiichi Sankyo will pay Merck & Co. Inc., $170 million upfront to bag commercialization and development rights of the latter’s test drug for.
Drugs
Health
Pharma
Roche ends small cell lung cancer trials as results show ‘reduced efficacy’
Swiss drugmaker, Roche, halted a lung cancer trial after it failed to meet the goal of progression-free survival compared to an existing treatment.
Drugs
Health
Pharma
USFDA gives nod to Amgen’s therapy for treating small cell lung cancer
HQ Team May 17, 2024: The US Food and Drug Administration has cleared Amgen’s drug to treat adult patients in the extensive stages.
Drugs
Health
Pharma
Merck to buy Harpoon for $680 million to step up cancer portfolio
HQ Team January 8, 2024: Merck & Co., will acquire Harpoon Therapeutics, Inc., for $680 million to expand its cancer drug portfolio —.